This project has received funding from the European Union’s 7th Framework Programme for research, technological development and demonstration under grant agreement no 611709
Subcribe to our mailing list
> Delivering value to European SMEs and entrepeneurs
Follow this project on F6S
Follow us on twitter
> Speed up the access to specialized treatment for patients with allergies
Type proposer: Pharmaceutical laboratory
Respiratory allergies are the most common allergies in Europe. Allergic rhinitis, conjunctivitis and asthma affects 400 to 500 million people worldwide (1-2). In France, it is estimated that up to one in three adults is affected by them (3).
People living in developed countries (specially children and teenagers) are and will be the most affected. Patients suffering this type of allergies currently require 8-10 years (with a worsen of symptoms) from initial symptom manifestation till specialized treatment to modify the disease (4-6).
There is a need to shorten this time to improve patient quality of life via faster access to effective treatment. Early treatment leads to a better control of the disease and has preventive effects (7-10).
 Bousquet J. Khaltaev N, Cruz AA, Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).Allergy. 2008 Apr;63 Suppl 86:8-160.
Pawankar R, Canonica G, Holgate S, Lockey R. WAO White Book on Allergy 2011-2012. In Edition Milwakee, Wisconsin, USA: WAO 2011.
 Klossek J-M. Un tiers des adultes ont une rhinite allergique en France – Enquête INSTANT. Presse médicale 2009; 38; 1220-1229
 Navarro A1, Colás C, Antón E, Conde J, Dávila I, Dordal MT, Fernández-Parre B, Ibáñez MD, Lluch-Bernal M, Matheu V, Montoro J, Rondón C, Sánchez MC, Valero A; Rhinoconjunctivitis Committee of the SEAIC. Epidemiology of allergic rhinitis in allergy consultations in Spain: Alergológica-2005. J Investig Allergol Clin Immunol. 2009;19 Suppl 2:7-13.
 Valero A1, Justicia JL, Antón E, Dordal T, Fernández-Parra B, Lluch M, Montoro J, Navarro AM. Epidemiology of allergic rhinitis caused by grass pollen or house-dust mites in Spain. Am J Rhinol Allergy. 2011;25(4):e123-8.
 Ibero M1, Justicia JL, Alvaro M, Asensio O, Domínguez O, Garde J, Sancha J, Valero A. Diagnosis and treatment of allergic rhinitis in children: results of the PETRA study. Allergol Immunopathol (Madr). 2012;40(3):138-43.
 Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
 Niggemann B, Jacobsen L, Dreborg S, et al: Five-year follow up on the PAT study: Specific immunotherapy and long-term prevention of asthma in children. Allergy 2006, 61:855-859.
 Jacobsen L, Niggemann B, Dreborg S, et al: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943-948.
 Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995,96:879-885.
Work on this challenge!
Health organisations across Europe are looking for innovative solutions to solve their needs. However, they don't know your solution exists, and they don't know that your exact solution can help solve their exact needs, but that's where we can help you.
If you have a solution or you want to work on this challenge, let us know!